Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog

American Journal of Physiology - Endocrinology and Metabolism

Volumn 305, Issue 12, 2013, Pages

  Moore, Mary Courtney ^a   Werner, Ulrich ^b   Smith, Marta S ^a   Farmer, Tiffany D ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Sanofi Deutschland GmbH   (Germany)

Author keywords

Hepatic glucose metabolism; Mixed meal; Type 2 diabetes

Indexed keywords

ALANINE; FATTY ACID; GLUCAGON; GLUCOSE; GLYCEROL; HYDROCORTISONE; INSULIN; LACTIC ACID; LIXISENATIDE; PARACETAMOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; EXPERIMENTAL DOG; FATTY ACID BLOOD LEVEL; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESPONSE; LIVER BLOOD FLOW; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH EMPTYING;

EID: 84890367732     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00354.2013     Document Type: Article

References (65)

1. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal- M). Diabetes Care 38: 2543-2550, 2013.
2. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28: 1936-1940, 2005.
3. Ameer B, Greenblatt DJ, Divoll M, Abernethy DR, Shargel L. High-performance liquid chromatographic determination of acetaminophen in plasma: singledose pharmacokinetic studies. J Chromatogr 226: 224-230, 1981.
4. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
5. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid 6: 67-79, 2011.
6. Becker RH, Stechl J, Kapitza C, Msihid J. Augmentation of 1st-phase insulin release with lixisenatide in non-diabetic subjects (Abstract). Diabetes 61: A296, 2012.
7. Beisswenger PJ. Glycation and biomarkers of vascular complications of diabetes. Amino Acids 42: 1171-1183, 2012.
8. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 44: 2107-2114, 2001.
9. Bueno L, Fioramonti J, Ruckebusch Y. Rate of flow of digesta and electrical activity of the small intestine in dogs and sheep. J Physiol 249: 69-85, 1975.
10. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48: 1503-1508, 1999.
11. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48: 1198-1214, 1999.
12. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 12: 503-513, 2009.
13. Christensen M, Knop FK, Vilsboll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 20: 549-557, 2011.
14. Coate KC, Kraft G, Lautz M, Smith M, Neal DW, Cherrington AD. A high-fat, high-fructose diet accelerates nutrient absorption and impairs net hepatic glucose uptake in response to a mixed meal in partially pancreatectomized dogs. J Nutr 141: 1643-1651, 2011.
15. Delgado-Aros S, Vella A, Camilleri M, Low PA, Burton DD, Thomforde GM, Stephens D. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 15: 435-443, 2003.
16. European Union. Community Register of Medicinal Products for Human Use, 2013 (Online). http://ec.europa.eu/health/documents/communityregister/html/h811.htm [10 April 2013].
17. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 35: 1225-1231, 2012.
18. Glerup H, Bluhme H, Villadsen GE, Rasmussen K, Ejskjaer N, Dahlerup JF. Gastric emptying: a comparison of three methods. Scand J Gastroenterol 42: 1182-1186, 2007.
19. Grubert JM, Lautz M, Lacy DB, Moore MC, Farmer B, Penaloza A, Cherrington AD, McGuinness OP. Impact of continuous and pulsatile insulin delivery on net hepatic glucose uptake. Am J Physiol Endocrinol Metab 289: E232-E240, 2005.
20. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16, 2004.
21. Hanefeld M, Temelkova-Kurktschiev T. Control of post-prandial hyperglycemia- an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutr Metab Cardiovasc Dis 12: 98-107, 2002.
22. Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 47: 415-421, 1973.
23. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 30: 81-101, 2013.
24. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
25. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089, 2003.
26. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 24: 1416-1421, 2001.
27. Lorenz M, Pfeiffer C, Steinsträßer A, Becker RH, Rütten H, Ruus P, Horowitz M. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes - Relationship to postprandial glycemia. Regul Pept 185: 1-8, 2013.
28. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88: 2719-2725, 2003.
29. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49: 452-458, 2006.
30. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54: 2212-2218, 2005.
31. Moore MC, Satake S, Lautz M, Soleimanpour SA, Neal DW, Smith M, Cherrington AD. Nonesterified fatty acids and hepatic glucose metabolism in the conscious dog. Diabetes 53: 32-40, 2004.
32. Nagell CF, Wettergren A, Ørskov C, Holst JJ. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667-672, 2006.
33. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
34. Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 96: 229-236, 2011.
35. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ. Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39: 113-118, 1996.
36. O'Connell SE, Zurzola FJ. A rapid quantitative determination of acetaminophen in plasma. J Pharm Sci 71: 1291-1294, 1982.
37. Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, Pijl H. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 299: E318-E324, 2010.
38. Parlevliet ET, Schroder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. J Pharmacol Exp Ther 328: 240-248, 2009.
39. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab 15: 1000-1007, 2013.
40. Plamboeck A, Veedfald S, Deacon CF, Hartmann B, Wettergren A, Svendsen LB, Meisner S, Hovendal C, Vilsbøll T, Knop FK, Holst JJ. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 304: G1117-G1127, 2013.
41. Porksen N, Grofte T, Greisen J, Mengel A, Juhl C, Veldhuis JD, Schmitz O, Rossle M, Vilstrup H. Human insulin release processes measured by intraportal sampling. Am J Physiol Endocrinol Metab 282: E695-E702, 2002.
42. Porksen N, Munn S, Steers J, Veldhuis JD, Butler PC. Effects of glucose ingestion versus infusion on pulsatile insulin secretion. The incretin effect is achieved by amplification of insulin secretory burst mass. Diabetes 45: 1317-1323, 1996.
43. Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 27: 1024-1032, 2010.
44. Ratner RE, Rosenstock J, Boka G, Silvestre L. Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract). Diabetologia 52: S60, 2010.
45. Rayner DV. The relationships between glucose absorption and insulin secretion and the migrating myoelectric complex in the pig. Exp Physiol 76: 67-76, 1991.
46. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36: 2489-2496, 2013.
47. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebocontrolled study (GetGoal-Duo 1). Diabetes Care 36: 2497-2503, 2013.
48. Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 36: 522-528, 2013.
49. Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Effects of the dipeptidyl peptidase- IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 31: 30-35, 2008.
50. Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, Gerich JE. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36: 2945-2951, 2013.
51. Rosenstock J, Ratner RE, Boka G, Silvestre L. Post-meal effects of AVE0010, a once-daily GLP-1 receptor agonist, in type 2 diabetes inadequately controlled on metformin (Abstract). Diabetes 58: A151, 2009.
52. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57: 2046-2054, 2008.
53. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes 51: 1663-1671, 2002.
54. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55: 243-251, 2006.
55. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21: 609-618, e21-e22, 2009.
56. Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14: 910-917, 2012.
57. No authors listed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998.
58. Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31: 108-113, 2008.
59. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56: 1475-1480, 2007.
60. Werner U, Gerlach M, Hofmann M, Herling AW. The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycemia (Abstract). Diabetes 56, Suppl 1: A129, 2007.
61. Werner U, Gerlach M, Hofmann M, Herling AW. Treatment of obese Zucker diabetic fatty rats with novel GLP-1 receptor agonist AVE0010 improves oral glucose tolerance and glycaemic control without risk of hypoglycaemia (Abstract). Diabetologia 49, Suppl 1: 398, 2006.
62. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 164: 58-64, 2010.
63. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9 -36)amide. Peptides 19: 877-882, 1998.
64. Woerle HJ, Albrecht M, Linke R, Zschau S, Neumann C, Nicolaus M, Gerich J, Göke B, Schirra J. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans. Am J Physiol Endocrinol Metab 294: E103-E109, 2008.
65. Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler Thromb Vasc Biol 32: 1513-1519, 2012.